Genmab — August 2019
-
"
GSK offentliggør ikke præcist hvad resultaterne af studiet viste, men vil senere give detaljer fra forsøget, der blev foretaget på 196 patienter. I øjeblikket har selskabet fire forsøg i gang med lægemidlet i knoglemarvskræft, og planlægger yderligere fem forskellige forsøg i knoglemarvskræft". -
-
Var det ikke den der gav sløret syn ?? Mener Jan nævnte det engang på et cc https://www.nature.com/articles/s41408-019-0196-6
-
Vestlige aktiemarkeder nede knap én procent i søndagshandel: http://www.proinvestor.com/investornyt/635408/vestlige-aktiemarkeder-nede-knap-en-procent-i-sondagshandel
-
God morgen
-
Daratumumab added to standard of care in patients with newly diagnosed multiple myeloma: A network meta‐analysis - https://onlinelibrary.wiley.com/doi/10.1111/ejh.13317#.XWG3vKDSINM.twitter
-
Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma - https://www.sciencedirect.com/science/article/pii/S1896112618303171
-
Vi er vist snart oppe igen kursmæssigt.
-
Pæn pris Amgen giver for et stof https://finance.yahoo.com/news/amgen-buy-celgenes-psoriasis-drug-121622595.html
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind